Maria E. Canziani

Sao Paulo, SP, Brazil

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.

Journal: Kidney international reports
Published: March 25, 2026

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.

Journal: Diabetes, obesity & metabolism
Published: February 03, 2026

Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD.

Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: May 13, 2025

Blood Pressure Variability in Older Patients with Chronic Kidney Disease.

Blood Pressure Variability in Older Patients with Chronic Kidney Disease.

Journal: Cardiorenal medicine
Published: September 10, 2024

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.

Journal: Lancet (London, England)
Published: October 05, 2023

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease.

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease.

Journal: PloS one
Published: January 08, 2023

The effects of medium cut-off and high-flux membranes on activated clotting time of patients on hemodialysis.

The effects of medium cut-off and high-flux membranes on activated clotting time of patients on hemodialysis.

Journal: Frontiers in nephrology
Published: December 29, 2022

High-volume hemodiafiltration decreases the pre-dialysis concentrations of indoxyl sulfate and p-cresyl sulfate compared to hemodialysis: a post-hoc analysis from the HDFit randomized controlled trial.

High-volume hemodiafiltration decreases the pre-dialysis concentrations of indoxyl sulfate and p-cresyl sulfate compared to hemodialysis: a post-hoc analysis from the HDFit randomized controlled trial.

Journal: Journal of nephrology
Published: December 06, 2021

Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.

Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.

Journal: American journal of physiology. Renal physiology
Published: February 01, 2020

Bowel Habits and the Association With Uremic Toxins in Non-Dialysis-Dependent Chronic Kidney Disease Patients.

Bowel Habits and the Association With Uremic Toxins in Non-Dialysis-Dependent Chronic Kidney Disease Patients.

Journal: Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
Published: October 19, 2018

Chronic kidney disease induces inflammation by increasing Toll-like receptor-4, cytokine and cathelicidin expression in neutrophils and monocytes.

Chronic kidney disease induces inflammation by increasing Toll-like receptor-4, cytokine and cathelicidin expression in neutrophils and monocytes.

Journal: Experimental cell research
Published: July 14, 2017

The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.

The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.

Journal: Kidney international
Published: November 18, 2015
Showing 1-12 of 22

Last Updated: 09/26/2026